. 2018 Oct 25;15(2):444–451. doi: 10.1080/21645515.2018.1533777

Table 2.

Comparison of Influenza HAI GMTs 1 Month After PCV13+QIV vs Placebo+QIV (Evaluable Immunogenicity Population).

	Vaccine Sequence (as Randomized)
	PCV13+QIV, placebo n^a = 427	Placebo+QIV, PCV13 n^a = 430	Vaccine Comparison
Strain	GMT^b (95% CI)^c	GMT^b (95% CI)^c	Ratio^d (95% CI)^e
A/H1N1	115 (104.0–126.8)	113 (101.6–124.7)	1.0 (0.88–1.18)
A/H3N2	226 (206.1–248.5)	196 (178.0–216.1)	1.2 (1.01–1.32)
B/Brisbane	28 (25.7–31.0)	26 (23.7–28.7)	1.1 (0.95–1.24)
B/Massachusetts	45 (41.0–50.3)	43 (39.1–48.2)	1.0 (0.90–1.21)

GMT = geometric mean titer; HAI = hemagglutination inhibition assay; PCV13 = 13-valent pneumococcal conjugate vaccine; QIV = quadrivalent inactivated influenza vaccine.

Underlined vaccine names indicate which immune response data for each study group are presented for comparison in the table.

^an = Number of subjects with a determinate HAI titer to the given strain.

^bGMTs were calculated using all subjects with available data for the specified blood draw.

^cCIs are back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

^dRatio of GMTs PCV13+QIV/placebo to placebo+QIV/PCV13 was calculated by back-transforming the mean difference between vaccine sequences on the logarithmic scale.

^eCIs for the ratio are back-transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (PCV13+QIV/placebo – placebo+QIV/PCV13).